CPT code 88130 represents a technical laboratory procedure to analyze sex chromatin (Barr bodies) in cells to assist in determining chromosomal sex. As a specialized cytogenetic/clinical laboratory test, it is ordered when cellular-level assessment of sex chromosomes is clinically relevant. Nationally, the code matters because it captures a distinct laboratory service with implications for clinical diagnosis, gender-related evaluations, and downstream genetic or endocrine workups. Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what CPT code 88130 covers, the clinical context in which the test is used, and the typical sites where the service is performed. The publication provides benchmark and coverage context for major payers, notes common billing modifiers and procedural components where applicable, and summarizes policy and coding considerations that affect reimbursement and claims submission. The content is geared toward clinicians, laboratory managers, and coding professionals seeking a clear, national-level understanding of the code, its clinical role, and administrative considerations. Data not available in the input is noted where applicable for readers seeking payer-specific rates or utilization metrics.